The Latest Trading Price of Kopran Ltd is ₹ 164.7 as of 30 Apr 15:30
. The P/E Ratio of Kopran Ltd changed from 7.4 on March 2021 to 21.9 on March 2025 . This represents a CAGR of 24.23% over 5 yearsThe P/E Ratio of MPS Pharmaa Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Kopran Ltd changed from ₹ 453.94 crore on March 2021 to ₹ 845.48 crore on March 2025 . This represents a CAGR of 13.25% over 5 yearsThe Market Cap of MPS Pharmaa Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Kopran Ltd for the Dec '25 is ₹ 194.35 crore as compare to the Sep '25 revenue of ₹ 117.93 crore. This represent the growth of 64.8% The revenue of MPS Pharmaa Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Kopran Ltd for the Dec '25 is ₹ 17.83 crore as compare to the Sep '25 ebitda of ₹ -5.25 crore. This represent the decline of -439% The ebitda of MPS Pharmaa Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Kopran Ltd changed from ₹ 11.1 crore to ₹ 9.34 crore over 7 quarters. This represents a CAGR of -9.39%
The net profit of MPS Pharmaa Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 53.94 % on March 2025 . This represents a CAGR of -0.49% over 5 yearsThe Dividend Payout of MPS Pharmaa Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Kopran Ltd
Kopran Limited, incorporated on April 26, 1958, was promoted by the Somani group and is a group company of Parijat Enterprises.
Company operates in two distinct business verticals.
While pharmaceutical formulations production is managed by Kopran Limited, manufacturing of API is operated under Kopran Research Laboratories Limited (KRLL).
Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs.
Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements.
About MPS Pharmaa Ltd
MPS Pharmaa Limited (Formerly known Advik Laboratories Limited) was incorporated in September, 1994.
The Company was promoted in by the Jains along with a group of dedicated professionals.
Presently, it is engaged in the manufacture and sale of pharmaceutical products in India.
It offers ethical, generic, and over the counter drugs in various formulations.
The company's generic product portfolio comprises antibacterial; antiallergics; antifungals; analgesic, antipyretic, and anti-inflammatory; antihypertensives; anthelminthics; antimalarials; corticosteroids; erectile dysfunction; gastrointestinal agents; sedatives; and other miscellaneous products.
The company commenced commercial production in 1997.
FAQs for the comparison of Kopran Ltd and MPS Pharmaa Ltd
Which company has a larger market capitalization, Kopran Ltd or MPS Pharmaa Ltd?
Market cap of Kopran Ltd is 795 Cr while Market cap of MPS Pharmaa Ltd is 3 Cr
What are the key factors driving the stock performance of Kopran Ltd and MPS Pharmaa Ltd?
The stock performance of Kopran Ltd and MPS Pharmaa Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Kopran Ltd and MPS Pharmaa Ltd?
As of May 3, 2026, the Kopran Ltd stock price is INR ₹164.7. On the other hand, MPS Pharmaa Ltd stock price is INR ₹1.73.
How do dividend payouts of Kopran Ltd and MPS Pharmaa Ltd compare?
To compare the dividend payouts of Kopran Ltd and MPS Pharmaa Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.